Literature DB >> 6279341

Specific in vitro antibody response to varicella zoster.

R L Souhami, J Babbage, R E Callard.   

Abstract

Peripheral blood mononuclear cells from normal donors were stimulated in vitro by varicella zoster (VZ) antigen and antibody measured by an ELISA technique. Antibody was produced in 14 of 19 individuals. This antibody was specific for VZ with no binding to herpes simplex virus (HSV), even when the mononuclear cells were taken from individuals who had circulating antibody to VZ and HSV. The failure of antibody production in mononuclear cell cultures from some normals, all of whom had serum antibody, was analysed using reciprocal combinations of E+ and E- cells from producers and non-producers. E+ cells from producers could help E- producer cells make antibody, but E+ cells from non-producers could not help E- cells from non-producers to do so. This result suggests a deficiency in circulating E- cells in non-producers. Four of four patients with untreated Hodgkin's disease were non-producers using blood mononuclear cell cultures, but their spleen cells produced antibody readily. This suggests that failure of in vitro antibody production in immune individuals may be due to sequestration of responsive B cells in spleen and other sites. This technique allows further study of the mechanisms of immunity to VZ in normal and immune-compromised individuals.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6279341      PMCID: PMC1536340     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

2.  An improved rosetting assay for detection of human T lymphocytes.

Authors:  M E Kaplan; C Clark
Journal:  J Immunol Methods       Date:  1974-07       Impact factor: 2.303

3.  Herpes Zoster-Varicella infections and lymphoma.

Authors:  D R Goffinet; E J Glatstein; T C Merigan
Journal:  Ann Intern Med       Date:  1972-02       Impact factor: 25.391

4.  Zoster, reinfection or activation of latent virus? Observations on the antibody response.

Authors:  L H Miller; P A Brunell
Journal:  Am J Med       Date:  1970-10       Impact factor: 4.965

5.  Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia.

Authors:  R W Armstrong; M J Gurwith; D Waddell; T C Merigan
Journal:  N Engl J Med       Date:  1970-11-26       Impact factor: 91.245

6.  Prevention of varicella by zoster immune globulin.

Authors:  P A Brunell; A Ross; L H Miller; B Kuo
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

7.  Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes.

Authors:  R E Callard; C M Smith
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

8.  Specific in vitro antibody response to influenza virus by human blood lymphocytes.

Authors:  R E Callard
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

9.  Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polyclonal activation.

Authors:  A S Fauci; K R Pratt; G Whalen
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

10.  Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease.

Authors:  J C Ruckdeschel; S C Schimpff; A C Smyth; M R Mardiney
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

  10 in total
  11 in total

1.  Limiting dilution analysis of specific in vitro anti-herpes simplex virus antibody production by human lymphocytes.

Authors:  M Yasukawa; Y Kobayashi
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes.

Authors:  O Pontesilli; P Carotenuto; M J Levin; D Suez; A R Hayward
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

3.  Human immune responses to herpes simplex virus, varicella-zoster and cytomegalovirus in vitro.

Authors:  S A Williamson; N Parish; J D Chambers; R A Knight
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

4.  Antibody to bacteriophage phi X 174 synthesized by cultured human peripheral blood lymphocytes.

Authors:  J Bohnsack; H D Ochs; R J Wedgwood; S R Heller
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

5.  Antibody-dependent cell-mediated cytotoxicity to Varicella zoster.

Authors:  J Babbage; A Sigfusson; R L Souhami
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

6.  Induction of a T-cell mediated suppressor activity by soluble products from antigen-specific helper/inducer human T-cell lines.

Authors:  A Fischer; P Beverley; M Feldmann; S Smith
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

7.  Defective in vitro antibody production to Varicella zoster and other virus antigens in patients with Hodgkin's disease.

Authors:  R L Souhami; J Babbage; A Sigfusson
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

8.  Defective B cell function in systemic lupus erythematosus.

Authors:  B K Pelton; A M Denman
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

9.  In vitro antigen-induced antibody responses to hepatitis B surface antigen in man. Kinetic and cellular requirements.

Authors:  T R Cupps; J L Gerin; R H Purcell; P K Goldsmith; A S Fauci
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

10.  Intrathecal antibody synthesis to virus antigens in multiple sclerosis.

Authors:  A Salmi; M Reunanen; J Ilonen; M Panelius
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.